Physician

Matthew Adam Fink, M.D.

According to 2025 Medicare claims, Matthew Fink, M.D. (NPI: 1033189246) practices hematology/oncology in the Tampa, FL market, with the plurality of this provider's patient population coming from Hillsborough, FL. This provider's primary affiliated billing organization is FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (NPI: 1760590962; TIN: 65-0825133) and primary practice location at 33607-6214.

Fink's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 756 traditional Medicare patients, billed 184,081 HCPCS/CPT codes, and received $2,443,444 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,048 prescription claims across 206 beneficiaries totaling $4,958,589 in drug costs, led by Revlimid (Lenalidomide). 2022 DME data shows 24 claims. Open Payments data shows 50 records totaling $1,657. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have risen steadily, from $569,540 to $4,958,589. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	1,091	209,484	$2,209,253
2016	1,111	211,001	$2,215,546
2017	1,092	252,543	$2,643,269
2018	1,160	229,021	$2,392,164
2019	1,135	287,161	$2,490,203
2020	1,027	259,184	$3,229,279
2021	866	225,223	$2,675,335
2022	752	197,124	$2,426,970
2023	779	216,233	$2,558,089
2024	756	184,081	$2,443,444

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	125	508	$569,540
2016	120	567	$993,232
2017	147	719	$1,433,506
2018	169	946	$2,368,829
2019	173	914	$1,886,116
2020	174	874	$2,162,548
2021	173	803	$2,067,828
2022	171	755	$2,053,813
2023	173	729	$2,559,906
2024	206	1,048	$4,958,589

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	88	$4,802
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	41	$5,451
2019	N/R	12	$1,794
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	24	$607
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	415	1,325	$94
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	323	692	$13
96372	Injection of drug or substance under skin or into muscle	172	774	$10
36415	Insertion of needle into vein for collection of blood sample	566	1,902	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	561	1,946	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	65	1,687	$1,060,792
Nubeqa	Darolutamide	62	1,860	$792,523
Ibrance	Palbociclib	34	952	$521,077
Lenvima	Lenvatinib Mesylate	18	535	$457,896
Brukinsa	Zanubrutinib	36	1,080	$396,749

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	50	$1,657	PFIZER INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Matthew Adam Fink, M.D.?

Tedicare shows public-source Medicare data for Matthew Adam Fink, M.D. (NPI 1033189246), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Matthew Adam Fink, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Matthew Adam Fink, M.D.?

Matthew Adam Fink, M.D. is linked to FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (billing NPI 1760590962) in the available physician profile data.

Does Matthew Adam Fink, M.D. have Open Payments data?

Matthew Adam Fink, M.D. has 50 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.